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Objective: Previous studies have reported that survivin expression is signiﬁcantly associated with various
malignancies including bladder cancer. However, the relationship between the expression of survivin
and the tumor stage and grade of bladder cancer still require further study.
Methods: To determine whether survivin plays a role in the differentiation of bladder cancer cells, we
conducted a preliminary study to examine the expression of survivin in bladder cancer cell lines.
Results: In this study, we observed that the gene expression fold changes of survivin ranged from 3.2 to
16.7 in various tumor grades (G1eG4) of bladder cancer cell lines, which were higher than that in normal
human urothelial cell line. With the worse differentiation of bladder cancer cell lines, the gene
expression fold changes of survivin increased signiﬁcantly (3.2-fold in RT4, 5.8-fold in 5637, 6.6-fold in
T24, and 16.7-fold in HT1197). In addition, we observed different genotypes among various cell lines (C/C
in HUC4449, C/G in RT4, C/G in 5637, G/G in T24, and C/C in HT1197). The relationship between survivin
31 C/G polymorphism and various bladder cancer cell lines was non-signiﬁcant. However, the over-
expression of survivin may be associated with aggressive features of bladder cancer.
Conclusion: Our ﬁndings suggest that survivin could be a potential therapeutic target through the in-
hibition of cell proliferation in bladder cancer.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Survivin is an inhibitor of apoptosis protein involved in anti-
apoptosis pathways.1 Survivin is generally expressed in embryonic
tissues and in various cancers, but it is almost undetectable inwell-
differentiated tissues.2 Therefore, survivin not only plays a critical
role in carcinogenesis but is also associated with the poor prognosis
of various cancers.3e5
Previous studies have reported that survivin expression is
signiﬁcantly associated with various malignancies, including
bladder cancer.6,7 Shariat et al8 observed that a high level oftment of Surgery, Shin-Kong
ipei 111, Taiwan.
ang).
ciation. Published by Elsevier Taiwsurvivin in urine is associated with the high tumor grades of
bladder cancer but not with the advanced tumor stages. Other
studies have reported that survivin is overexpressed in tumor cells
but not in normal urothelial cells.9,10 However, the relationship
between the expression of survivin and the tumor stage and grade
of bladder cancer require further investigation.
To determine whether survivin plays a role in the differentiation
of bladder cancer cells, we conducted a preliminary study to
examine the expression level of survivin in bladder cancer cell lines.2. Methods
The survivin expression in ﬁve cell lines, HUC4449 (normal hu-
man urothelial cell line), RT4 [human urinary bladder papilloma cell
line; tumor grade 1 (G1)], 5637 [human bladder carcinoma cell line;
tumor grade 2 (G2)], T24 [human bladder carcinoma cell line; tumoran LLC. Open access under CC BY-NC-ND license.
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grade 4 (G4)], was examined using a reverse transcription polymer-
ase chain reaction (PCR) and real-time PCR. Total RNA was isolated
from 1  106 normal human urothelial cells: HUC4449 (ScienCell
Research Lab, Carlsbad, CA, USA) and 1106 cells from four bladder
cancer cell lines [Bioresource Collection and Research Center (BCRC),
Hsinchu City, Taiwan]: RT4 (BCRC60111), 5637 (BCRC60061), T24
(BCRC60062), and HT1197 (BCRC60059), by using a Trizol reagent
(Invitrogen, Carlsbad, CA, USA), and the total RNA (1.5 ug) was then
transcribed to cDNA by using Oligo(dT)15 primers and an ImPromII
reverse transcription system (Promega Corporation, Madison, WI,
USA) according to the manufacturers’ instructions.
The expression level of the survivin transcript was determined
using real-time PCR and an ABI instrument (ABI7500; ABI, Foster
City, CA, USA). The survivin primers were used from position A07
(Unigene Hs.514527) in an RT2 Proﬁler PCR array system (SABio-
sciences Corporation, Frederick, MD, USA). The survivin expression
level was normalized using a housekeeping gene (GAPDH) as the
internal reference to control the loading difference. The following
formula was used to calculate the relative gene expression level:
2DCt is DCt ¼ Ct (GOI)  avg. [Ct (HKG)], where GOI is each gene of
interest, and HKG is the housekeeping gene. The fold change
(2DDCt) is the ratio of the bladder cancer cell line to the normal
urothelial cell line.
In addition, the31C/G polymorphism (rs9904341) located in the
promoter region of the survivin gene, was determined using PCR-
restricted fragment length polymorphism. For the survivin 31 C/G
polymorphism, the speciﬁc primers used were 50-GTTCTTTGAAAGC
AGTCGAG-30 (sense) and 50-GCCAGTTCTTGAATGTAGAG-30 (anti-
sense). The PCR conditions were one cycle at 95C for 5 minutes; 35
cycles of 95C for 30 seconds, 58C for 60 seconds and 72C for 60
seconds and aﬁnal extension at 72C for 5minutes. The genotypes (C/
C: 341 bp; C/G: 341 bp, 236 bp, and 105 bp; and G/G: 236 bp and
105bp)weredeterminedafterdigestionwithEcoO109I (NewEngland
Biolabs, Ipswich, MA, USA) at 37C overnight.
3. Results
Based on our preliminary results, the gene expression fold
changes of survivin ranged from 3.2 to 16.7 in various tumor grades
of bladder cancer cell lines (RT4, G1; 5637, G2; T24, G3, and HT1197,
G4), which were higher than that in normal human urothelial cell
line (HUC4449; Fig. 1). With the worse differentiation of bladder
cancer cell lines, the gene expression fold changes of survivin (3.2-Fig. 1. Expression of survivin in one normal human urothelial cell line (HUC4449) and
four bladder cancer cell lines: RT4 [human urinary bladder papilloma cell line; tumor
grade 1 (G1)], 5637 [human bladder carcinoma cell line; tumor grade 2 (G2)], T24
[human bladder carcinoma cell line; tumor grade 3 (G3)], and HT1197 [human bladder
carcinoma cell line; tumor grade 4 (G4)]. Mean mRNA expression levels in 5 cell lines
were determined using real-time quantitative reverse transcription polymerase chain
reaction. Data were calculated relative to the normal urothelial cell line set to 1.0,
normalized against GAPDH mRNA levels. The vertical bars represent the standard error
(n ¼ 3).fold in RT4, 5.8-fold in 5637, 6.6-fold in T24, and 16.7-fold in
HT1197) signiﬁcantly increased (p ¼ 0.034). We also detected the
survivin 31 C/G polymorphism in various cell lines. The PCR
product of survivin is 341 bp (Fig. 2A). The digested PCR products
were determined using 2.5% agarose gel electrophoresis and the
corresponding genotypes are shown in Fig. 2B (C/C in HUC4449, C/
G in RT4, C/G in 5637, G/G in T24, and C/C in HT1197).
4. Discussion
Bladder cancer is one of the most commonmale malignancies in
Taiwan. Survivin, an inhibitor of apoptosis protein, has been re-
ported to play a role in carcinogenesis, and is associated with poor
clinical outcomes in various cancers.3 A previous study evaluated
the association between the survivin 31 C/G polymorphism and
urothelial carcinoma (UC).11 Themajor ﬁndings were: (1) compared
with individuals carrying the G/G genotype of the survivin gene,
signiﬁcantly increased UC risks of 2.8 and 4.0 were observed for
those who carried the C/G genotype and those who carried the C/C
genotype, respectively; (2) those who have ever smoked and car-
ried the C/G and C/C genotypes of the survivin gene have a signif-
icantly higher UC risk of 5.6; and (3) UC cases carrying the C/C
genotype of the survivin gene have a signiﬁcantly higher preva-
lence of having muscle-invasive or higher-grade tumors, compared
with those carrying the G/G genotype. However, the clinical
application of survivin in bladder cancer requires further study.
In the present study, we used an in vitro approach to evaluate
the expression of survivin in various bladder cancer cell lines. The
gene expression fold changes of survivin ranged from 3.2 to 16.7 in
various tumor grades of bladder cancer cell lines, which were
higher than that in normal human urothelial cell line (Fig. 1). These
ﬁndings imply that the increasing expression of survivin isFig. 2. Polymerase chain reaction (PCR)-restricted fragment length polymorphism
analysis of the survivin 31 C/G polymorphism. (A) The ampliﬁed PCR product of the
survivin gene is 341 bp. (B) The PCR products were digested with EcoO109I and
analyzed using 10% acrylamide gel. M: DNA ladder (MBI Fermentas, Amherst, NY, USA).
C/C genotype: 341 bp (HUC4449 and HT1197); C/G genotype: 341, 236 bp and 105 bp
(RT4 and 5637) and G/G genotype: 236 bp and 105 bp (T24).
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cancer cells.
A previous study indicated that the lack of a promoter region in
the survivin gene can lead to a deﬁciency of cell cycle-dependent
expression in HeLa cells.12 Therefore, we also examined the
survivin 31 C/G polymorphism in bladder cancer cell lines. Our
results did not reveal a signiﬁcant relationship between
survivin 31 C/G polymorphism and various tumor grades of
bladder cancer cell lines, possibly because the gene expression level
or enzyme activity of survivin is modulated by single nucleotide
polymorphisms or epigenetic changes in other susceptible genes.
According to a review of the literature, this is the ﬁrst in vitro
study to investigate the expression of survivin in various bladder
cancer cell lines. With the worse differentiation of bladder cancer
cell lines, the gene expression fold changes of survivin signiﬁcantly
increased in this study. Although the relationship between the
survivin 31 C/G polymorphism and various tumor grades of
bladder cancer cell lines was not signiﬁcant, additional studies with
larger sample size are required to clarify the relationship between
genotypes and phenotypes in various ethnic groups.
The present study has some limitations. First, we only examined
the expression of survivin in several bladder cancer cell lines. Our
ﬁndings should be further validated by using bladder cancer tumor
tissues. Second, we investigated only one polymorphism, which
incompletely represents the entire function of survivin gene. More
functional polymorphisms of the survivin gene should be included
to examine the combined effects on bladder cancer risk. Therefore,
the ﬁndings of our analyses should be interpreted with caution.
In conclusion, the overexpression of survivin was signiﬁcantly
associated with an aggressive clinical behavior of bladder cancer.
Theseﬁndings suggest that survivin could be a potential therapeutic
target through inhibition of cell proliferation in bladder cancer.13e15
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